CU Denver and UC San Francisco teams are independently performing whole-genome sequencing to find genes involved in reduced efficacy of a common bronchodilator drug.
In PNAS this week: DNA damage associated with e-cigarette exposure, inflammasome inhibition by OLT1177, and more.
The organizations in the consortium will identify, characterize, and catalog human biological molecules affected by physical activity in volunteer biosamples.
Vanderbilt University, the University of Colorado at Denver, Partners HealthCare, and the Montreal Heart Institute will use Illumina technology to analyze their biobank samples.
The new findings point towards creating different treatment strategies for combating the disease in old and young patient groups.
The partners will evaluate whether circulating tumor DNA profiling has use for monitoring treatment response and relapse in melanoma patients.
Kauffman Foundation, MIT, BioAMPS, University of Colorado, Endo Pharma, Harvard, Galapagos, Flanders Institute of Biotechnology, and more …
Funding from the National Institutes of Health for all proteomics-related research shrank by almost 3 percent in fiscal 2008, according to an analysis of NIH data by ProteoMonitor.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.